Successful treatment of a progressive BRAF V600E-mutated anaplastic pleomorphic xanthoastrocytoma with vemurafenib monotherapy

Journal of Clinical Oncology

Volumn 34, Issue 10, 2016, Pages e87-e89

  Lee, Eudocia Q ^a,b   Ruland, Sandra ^a   Leboeuf, Nicole R ^a   Wen, Patrick Y ^a,b   Santagata, Sandro ^b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID DERIVATIVE; TEMOZOLOMIDE; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; GLUTAMIC ACID; INDOLE DERIVATIVE; SULFONAMIDE; VALINE;

ADULT; ALLERGIC REACTION; ALOPECIA; ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; DIARRHEA; DISEASE COURSE; EDEMA; EXON; HEADACHE; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; LYMPHOCYTIC INFILTRATION; MALE; MEASLES LIKE RASH; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEOMORPHIC XANTHOASTROCYTOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUNCH BIOPSY; PYROSEQUENCING; RADIATION DOSE; SEIZURE; TREATMENT RESPONSE; XEROSIS; ASTROCYTOMA; BRAIN NEOPLASMS; CANCER STAGING; DRUG ADMINISTRATION; DRUG ERUPTIONS; FRONTAL LOBE; GENETICS; MUTATION; PATHOLOGY; TEMPORAL LOBE; TREATMENT OUTCOME; XANTHOMATOSIS;

ADULT; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FRONTAL LOBE; GLUTAMIC ACID; HUMANS; INDOLES; MAGNETIC RESONANCE IMAGING; MALE; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; TEMPORAL LOBE; TREATMENT OUTCOME; VALINE; XANTHOMATOSIS;

EID: 84963593691     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.1766     Document Type: Article

References (18)

1. Perkins SM, Mitra N, Fei W, et al: Patterns of care and outcomes of patients with pleomorphic xanthoastrocytoma: A SEER analysis. J Neurooncol 110:99-104, 2012
2. Gallo P, Cecchi PC, Locatelli F, et al: Pleomorphic xanthoastrocytoma: Long-term results of surgical treatment and analysis of prognostic factors. Br J Neurosurg 27:759-764, 2013
3. Horbinski C: To BRAF or not to BRAF: Is that even a question anymore? J Neuropathol Exp Neurol 72:2-7, 2013
4. MacConaill LE, Campbell CD, Kehoe SM, et al: Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 4:e7887, 2009
5. Rush S, Foreman N, Liu A: Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol 31:e159-e160, 2013
6. Jones DT, Kocialkowski S, Liu L, et al: Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68:8673-8677, 2008
7. Dias-Santagata D, Lam Q, Vernovsky K, et al: BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: Diagnostic and therapeutic implications. PLoS One 6:e17948, 2011
8. Schindler G, Capper D, Meyer J, et al: Analysis of BRAF V600E mutation in 1, 320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397-405, 2011
9. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
10. Bollag G, Tsai J, Zhang J, et al: Vemurafenib: The first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 11:873-886, 2012
11. Rochet NM, Kottschade LA, Markovic SN: Vemurafenib for melanoma metastases to the brain. N Engl J Med 365:2439-2441, 2011
12. Kolar GR, Miller-Thomas MM, Schmidt RE, et al: Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib. J Clin Oncol 31:e40-e43, 2013
13. Dummer R, Rinderknecht J, Goldinger SM, et al: An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J Clin Oncol 29:537s, 2011(suppl; abstr 8548)
14. Nicolaides TP, Li H, Solomon DA, et al: Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 17:7595-7604, 2011
15. Wen PY, Macdonald DR, Reardon DA, et al: Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 28:1963-1972, 2010
16. Brandsma D, Stalpers L, Taal W, et al: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453-461, 2008
17. Chamberlain MC, Glantz MJ, Chalmers L, et al: Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82:81-83, 2007
18. Sullivan RJ, Flaherty KT: Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 49:1297-1304, 2013